Follow The Filings

PAHC Phibro Animal Health

Phibro Animal Health earnings company data as of 8:02 PM ET 10/22

  • 1 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS 0.77 — —
Rev — — —
FY2027 Q4 26 Aug EPS 0.72 0.85 Beat +18.1%
Rev — $396.7M —

Insider trades

Open-market buys and sales by PAHC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PAHC insider trades
  • $318K bought by 1 insider
  • None no sales outside a trading plan
  • $28.9M sold by 1 insider under 10b5-1 plans
  1. E Thomas Corcoran Director
    Buy
    $318K 10,000 shares at $31.77 +32% to stake
    Traded May 29 Filed Jun 2
    ↗
  2. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1M 18,608 shares at $54.61 25% of stake
    Traded May 5–7 Filed May 7
    ↗
  3. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.1M 21,120 shares at $53.86 22% of stake
    Traded Apr 28–30 Filed Apr 30
    ↗
  4. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.2M 21,120 shares at $54.79 18% of stake
    Traded Apr 21–23 Filed Apr 23
    ↗
  5. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.2M 21,120 shares at $56.89 15% of stake
    Traded Apr 14–16 Filed Apr 16
    ↗
  6. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $757K 14,080 shares at $53.75 27% of stake
    Traded Mar 30–31 Filed Mar 31
    ↗
  7. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.2M 21,120 shares at $55.21 29% of stake
    Traded Mar 24–26 Filed Mar 26
    ↗
  8. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.2M 22,880 shares at $52.40 24% of stake
    Traded Mar 17–19 Filed Mar 19
    ↗
  9. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $258K 5,280 shares at $48.91 5.2% of stake
    Traded Mar 13 Filed Mar 16
    ↗
  10. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $1.1M 21,120 shares at $52.27 94% of stake
    Traded Feb 24–26 Filed Feb 26
    ↗
  11. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $716K 14,080 shares at $50.84 38% of stake
    Traded Feb 19–20 Filed Feb 23
    ↗
  12. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $728K 14,080 shares at $51.68 28% of stake
    Traded Feb 13–18 Filed Feb 18
    ↗
  13. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $3.7M 72,198 shares at $51.77 59% of stake
    Traded Feb 10–11 Filed Feb 11
    ↗
  14. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $5.4M 110,842 shares at $48.38 47% of stake
    Traded Feb 5 Filed Feb 9
    ↗
  15. Jack Bendheim CEO, +1 joint filer
    Planned sale
    $545K 13,180 shares at $41.39 21% of stake
    Traded Feb 3–4 Filed Feb 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 10 conversions, 8 stock grants, 7 other transactions, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.